Humpath.com - Human pathology

Home > G. Tumoral pathology > Molecular pathology of tumors > Genetic anomalies > Mutation testing > Cancer gene assays from FFPE > BRAF assays from FFPE

BRAF assays from FFPE

Wednesday 7 December 2011

Activating mutations of the BRAF and KRAS genes cause constitutive stimulation of an important cell-signaling pathway promoting tumorigenesis, and are increasingly recognized as determinants of response to targeted cancer therapies.

The BRAF-V600E mutation accounts for most of the BRAF mutations in cancer, and KRAS mutations are predominantly encoded by nucleotide substitutions within codons 12 and 13.

The BRAF V600E mutation is detected in about 13% of the colorectal cancers.

The frequency of KRAS mutations is about 32%, with G>A transitions at position 2 of codons 12 and 13 being most prevalent.

References

- Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Packham D, Ward RL, Ap Lin V, Hawkins NJ, Hitchins MP. Diagn Mol Pathol. 2009 Jun;18(2):62-71. PMID: 19430299